Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.
You may also be interested in...
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Patient enrollment in clinical trials for cancer drugs was "severely" affected by the COVID-19 pandemic, according to a report published in Nature Reviews Drug Discovery.